Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to -$21.2 million.

  • Abeona Therapeutics' Cash from Operations fell 7318.13% to -$21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$74.9 million, marking a year-over-year decrease of 5389.29%. This contributed to the annual value of -$56.0 million for FY2024, which is 5135.51% down from last year.
  • Latest data reveals that Abeona Therapeutics reported Cash from Operations of -$21.2 million as of Q3 2025, which was down 7318.13% from -$18.8 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Cash from Operations high stood at -$5.7 million for Q3 2023, and its period low was -$30.3 million during Q4 2021.
  • In the last 5 years, Abeona Therapeutics' Cash from Operations had a median value of -$12.7 million in 2024 and averaged -$13.7 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 177931.68% in 2021, then surged by 5375.62% in 2022.
  • Abeona Therapeutics' Cash from Operations (Quarter) stood at -$30.3 million in 2021, then surged by 53.76% to -$14.0 million in 2022, then surged by 34.0% to -$9.2 million in 2023, then crashed by 79.31% to -$16.6 million in 2024, then dropped by 27.95% to -$21.2 million in 2025.
  • Its Cash from Operations was -$21.2 million in Q3 2025, compared to -$18.8 million in Q2 2025 and -$18.4 million in Q1 2025.